AIM/CD5L as a potential immunomodulator in feline injection-site sarcoma
AIM/CD5L may promote an immunosuppressive tumor microenvironment in feline injection-site sarcoma by influencing macrophage behavior.
Asset / Drug
Drug and asset intelligence for AIM with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.